Abstract 4363
Background
Hormonal therapy (HT) is generally proposed to all patients with endocrine receptor positive breast cancer to reduce the risk of recurrence and death. However, HT is associated with side effects. The aim of the present study was to determine the preferences of women treated with adjuvant HT for breast cancer.
Methods
Preferences have been elicited with a self-completed, validated questionnaire administered at study entry in eligible patients. The questionnaires, showing hypothetical scenarios based on potential survival times (5 or 15 years) and rates (60% or 80% at 5 years) without HT, were used to determine the lowest gains women judged necessary to make the treatment. The analyses were conducted into three different groups of early breast cancer patients to evaluate the expected survival benefit before starting HT (A), after a few months from the beginning (B) and after several years of HT (C). Patients also completed psychological questionnaires and the patient reported symptoms form.
Results
A total of 452 patients were included in the study: 149 in group A, 150 in group B and 153 in group C. In group C, 65% of patients were receiving HT with aromatase inhibitors (with or without a LHRH analogue). 12%, 24% and 35% of patients received adjuvant chemotherapy in group A, B and C, respectively. Overall, 355 women (79%) had children. The responses were quite similar between the three groups. A mean gain of 13 years was judged necessary to make adjuvant endocrine therapy worthwhile based on the hypothetical scenario of untreated mean survival time of 15 years. A mean gain of 22% more women surviving was judged necessary to make adjuvant HT worthwhile based on an untreated 5-year survival rate expectation of 60%. Cognitive dysfunction was considered the side effect least compatible with the continuation of treatment in all three groups. The willingness to continue therapy was unrelated to age, marriage and presence of children.
Conclusions
This is a large study of patient preferences on HT. Preferences have been elicited also in premenopausal patients treated with aromatase inhibitors. Compared with other studies with similar design, the patients included in the present study required larger benefits to make adjuvant therapy worthwhile.
Clinical trial identification
NCT 03939156 Release date 05.03.2019.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Women cancer center.
Disclosure
E. Montagna: Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: gentili; Advisory / Consultancy: Novartis. M.A. Colleoni: Honoraria (self): Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Pfizer; Advisory / Consultancy: OBI Pharma; Advisory / Consultancy: Puma Biotechnology; Advisory / Consultancy: Celldex; Advisory / Consultancy: AstraZeneca. G. Cancello: Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: gentili. E. Munzone: Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Genomic Health. S. Dellapasqua: Travel / Accommodation / Expenses: Roche. M. Mazza: Advisory / Consultancy: Novartis; Advisory / Consultancy: Gentili; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Celgene; Advisory / Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract
5612 - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia
Presenter: Elena Shagimardanova
Session: Poster Display session 2
Resources:
Abstract